BNTX BioNTech SE - ADR

$BNTX Going to 80's. Leaderless until February. Their technology did not work and the best ideas are walking out the door with the CEO's and CMO's departure. Just a company wondering in the desert and all their supplies taken.

$BNTX This is a "no touch". Really amazing that the CEO and CMO are leaving to establish a new and separate company with BNTX technology. When does the new CEO arrive that has no mRNA experience? ANSWER: February 2027. So, let's get this straight, the current CEO is negotiating with himself on terms to use and take BNTX technology. You see the governance and conflict of interest issue? BNTX presentation on Lung-107 pivotal on Sunday. So far, just a string of clinical failures. This company is leaderless.

$BNTX Perhaps the biggest stock failure in the last 12 months. mRNA technology was so promising and BioNtech just squandered it all. Thankfully, I jettisoned this company early 2026 and went all in on Moderna. Any reason for a second look? Seems like dead money until new leadership takes the helm next year. Any catalysts between now and March of next year? They promised many positive surprises in 2026. 2026 was to be a great year . . .anyone?

$BNTX You fools think the science will make this move like Moderna but clearly the market doesn’t give a shit about the science. Moderna moved because it experienced a short squeeze, this doesn’t have the same setup. Furthermore it’s an ADR, and US equities experience the most volatility. It also doesn’t help that the founders dipped and that executive team members also sold shares recently. This is a multi-year play if they execute correctly, so don’t expect the same type of rise here.

$BNTX Soon, BNTX’s MC will surpass MRNA’s, as more and more details come out of the respective pipeline. JMO

$BNTX Disappointments mostly built in the current pathetic stock price. Will hold steady until BNT 327, 323, and 316 are proven fully successful. JMO

$BNTX Fake companies like moderna up 250 % + the past few months & novavax up But bntx stuck on stupid

$BNTX Doesn’t go up when Moderna goes up, goes down when Moderna goes down. Likely will see $80 before it sees $100 here. Major updates on its pipeline won’t come for years hear and who knows how the market will look like then. I am lowering my expectations on this from $90 to $80 with sector risk if Moderna continues going down.

$BNTX This company is developing something similar to what you $BNTX are working on—a melanoma cancer vaccine. It's still really undervalued, and the data released yesterday looks very promising and highly competitive. Let's get rich together!! Buy some shares while it's still cheap!

$BNTX looking to add my way to a thousand shares by end of next year. Some discounts along the way shall help. So I appreciate the shorts.

$BNTX treating late stage unresectable is always hard vs early stage (eg Moderna ) so this is the likely scenario Pumitamig and gotistobart still in play

BioNTech’s Cancer Drug Misses A Key Trial Goal – Citi Says Survival Data Could Preserve ‘A Meaningful Development Path’ $BNTX $XBI https://stocktwits.com/news/equity/markets/bio-n-tech-s-cancer-drug-misses-a-key-trial-goal-citi-says-survival-data-could-preserve-a-meaningful-development-path/cZxBViFRBYa

$BNTX 🏥 BioNTech SE reported that its Phase 2/3 AHEAD-MERIT trial of BNT113 plus pembrolizumab did not meet the first dual primary endpoint of progression-free survival in metastatic HPV16-positive head and neck cancer, while the trial continues to evaluate overall survival.

$BNTX LOL this stock didn’t even go up with Moderna, and it’s likely to drop today with it. Like I said previously, ADRs are treated differently, and that you all won’t get the same response as Moderna. Expect this to sideline for the next year or so.

BNTX Stock Selloff Deepens Doubts: BMO Ties BNT113 Miss To Wider mRNA Cancer Vaccine Struggles $BNTX $FBT $IBB https://stocktwits.com/news/equity/markets/bntx-stock-selloff-deepens-doubts-bmo-ties-bnt-113-miss-to-wider-m-rna-cancer-vaccine-struggles/cZxBx6kRBYA

$BNTX German mRNA drugmaker BioNTech's BNT113 missed its first primary endpoint in head and neck cancer: adding it to pembrolizumab gave no significant progression-free survival gain. BioNTech had €16.6 billion in cash, cash equivalents and security investments, Q2 2026 revenues of €105.6 million and full-year 2026 revenue guidance of €1.6–1.9 billion; BNT113 was one of its expected 2026 late-stage readouts. Shares closed $95.82 Oct 12, 2026. Other side: trial runs on; a significant overall-survival result would still make it positive, no date given.

BioNTech reported that its experimental mRNA cancer immunotherapy BNT113 failed to achieve a statistically significant improvement in progression-free survival when combined with pembrolizumab versus pembrolizumab alone in the Phase 2/3 AHEAD-MERIT trial for HPV16-positive head and neck squamous cell carcinoma. The company said the results support continued evaluation of BNT113 and indicate activation of its intended therapeutic mechanism. The trial will continue assessing overall survival, its second primary endpoint, following a recommendation from the independent data monitoring committee. The setback adds to pressure on BioNTech following recent analyst price-target cuts. Bank of America’s Tazeen Ahmad lowered her target to $114 from $122 while maintaining a Buy rating, removing the discontinued FixVac and iNeST programs from her valuation model. Morgan Stanley also trimmed its price target. $BNTX

$BNTX Up about 5% Friday on the NYT's report that the NIH wants a national push to speed up personalized cancer vaccines, a public-private program starting in December aimed first at pancreatic, liver and colorectal cancers. One wrinkle: BioNTech and Genentech scrapped their Phase 2 colorectal mRNA vaccine trial back in August after an independent board concluded follow-up was unlikely to change the weak efficacy readout. Colorectal is one of the NIH program's starting indications.

$BNTX Are you sure BNTX stock is controlled by the American stock markets? They trade the ADR, but the actual stock trades on the German exchanges. A stock and its ADR are not the same thing, and will often move differently from one another.